<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01095172</url>
  </required_header>
  <id_info>
    <org_study_id>RituxiRT</org_study_id>
    <secondary_id>2009-017066-23</secondary_id>
    <secondary_id>95769119</secondary_id>
    <secondary_id>9154</secondary_id>
    <nct_id>NCT01095172</nct_id>
  </id_info>
  <brief_title>RituxiMab INDuction in Renal Transplantation</brief_title>
  <acronym>ReMIND</acronym>
  <official_title>A Randomized Trial of Rituximab in Induction Therapy for Living Donor Renal Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Europe Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis:

        -  That B cell depletion, rather than reducing acute rejection, will allow minimisation of
           immunosuppression, which may lead to better graft survival.

      Aim:

        -  To assess whether the addition of rituximab to a low-dose tacrolimus immunosuppression
           regime allows a reduction in steroid administration.

      Objectives:

        -  To assess whether B cell depletion affects graft function, acute rejection and
           complication rates

        -  To assess whether the T cell response to allotransplantation is impaired by B cell
           depletion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Estimated GFR (calculated using the Cockcroft-Gault formula)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biopsy proven acute rejection (based on Banff classification)</measure>
    <time_frame>1, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Allograft survival</measure>
    <time_frame>1, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival</measure>
    <time_frame>1, 2, 3, 4, 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>1 year</time_frame>
    <description>New episodes, including (but not restricted to) viral (e.g. CMV, EBV), bacterial (e.g. Urinary Tract Infections with details of causative organism) and fungal infections will be recorded at each assessment time-point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in B and T cell repertoire</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">612</enrollment>
  <condition>Function of Renal Transplant</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rituximab 375mg/m2
Low dose tacrolimus with mycophenylate mofetil, hydrocortisone and 1 week prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose tacrolimus with mycophenylate mofetil and continued prednisolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m^2, single dose given 2-4 weeks prior to transplantation</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>dose calculated to give levels of 3-7ng/ml</description>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>Advagraf, Adoport, Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenylate mofetil</intervention_name>
    <description>Mycophenylate mofetil 2g/day in divided doses</description>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
    <other_name>MMF, Cellcept</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients over 18 years receiving their first living donor renal transplant, or
             their second if the first was not lost from acute rejection

          -  Patients who have given written informed consent

          -  Women of child bearing potential taking adequate contraception.

        Exclusion Criteria:

          -  Previous other organ transplants lost through acute rejection

          -  Patients undergoing antibody incompatible transplantation

          -  Patients with other organ transplants

          -  Patients previously treated with cyclophosphamide, ATG, OKT3 or rituximab

          -  Patients with white cell count below 4.0x10^9/L.

          -  Patients with platelet count below 100x10^9/L

          -  Patients who are treated with drugs that are strong inhibitors or inducers of
             cytochrome P450, or treated with terfenadine, astemizole, cisapride or lovastatin

          -  Patients who have been involved in any other investigational trial or non protocol
             immunosuppressive regimen in the previous 90 days prior to transplant

          -  Pregnant or breastfeeding women

          -  Patients with a documented history of malignancy and its origins and treatment in the
             last five years. (Localised basal cell carcinoma of the skin is permitted)

          -  Patients known to be HIV, Hepatitis B surface antigen or Hepatitis C antibody positive

          -  Patients who in the opinion of the Investigator would not be a suitable candidate for
             study participation

          -  Women of child bearing potential not willing to take adequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nizam Mamode, MD FRCS(Gen)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nizam Mamode, MD FRCS(Gen)</last_name>
    <phone>+44 20 7188 1543</phone>
    <email>nizam.mamode@gstt.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicholas Barnett, MRCS</last_name>
    <email>nicholas.barnett1@gstt.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>South West Transplant Centre</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy Coles</last_name>
      <email>mandyreynolds@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jamie Barwell, FRCS MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>East Kent Hospitals NHS Foundation Trust</name>
      <address>
        <city>Canterbury</city>
        <state>Kent</state>
        <zip>CT1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Webb, MD, MRCP</last_name>
      <email>Michelle.Webb@ekht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Michelle Webb, MD, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Glasgow Renal and Transplant Unit</name>
      <address>
        <city>Glasgow</city>
        <zip>G11 6NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Clancy, PhD FRCS</last_name>
      <email>Marc.Clancy@ggc.scot.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Marc Clancy, PhD FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nizam Mamode, MD FRCS(Gen)</last_name>
      <phone>+44 20 7188 1543</phone>
      <email>nizam.mamode@gstt.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Nicholas Barnett, MRCS</last_name>
      <email>Nicholas.Barnett1@gstt.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Nizam Mamode, MD FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicholas Barnett, MRCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Griffin, PhD</last_name>
      <email>Clare.Griffin@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Neil Parrott, MD FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Kidney Institute</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Badri Shrestha, MPhil FRCS</last_name>
      <email>Badri.Shrestha@sth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Badri Shrestha, MPhil FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2010</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guy's and St Thomas' NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Nizam Mamode</investigator_full_name>
    <investigator_title>Consultant Surgeon and Reader in Transplant Surgery</investigator_title>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Rituximab</keyword>
  <keyword>B cell</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

